Hidden coeliac disease in patients suffering from oral lichen planus. by Compilato, D. et al.
LETTERS TO THE EDITOR
Hidden coeliac disease in
patients suffering from oral
lichen planus
Editor
Coeliac disease (CD) is a chronic immune-mediated disease, trig-
gered by gluten ingestion in genetically susceptible subjects result-
ing in small intestinal mucosal injury with subsequent nutrient
malabsorption.1 CD is a disease with a heterogeneous and often
unsuspected range of clinical presentations; its ‘typical’ presenta-
tion, characterized by a gastrointestinal manifestations, is less
frequent and many CD patients show ‘atypical’ – non-gastroenter-
ological – signs, as some oral lesions (e.g. recurrent aphthous sto-
matitis, dental enamel defects and unspecific atrophic glossitis).1
In this regard, few studies have analysed the association of CD and
oral lichen planus (OLP).2–5 In this study, we assessed the fre-
quency of unrevealed CD among OLP patients and the possible
effects of a gluten-free diet (GFD) on OLP lesions in CD patients.
Twenty-three patients with clinically and histologically con-
firmed OLP, receiving topical corticosteroid treatment underwent
blood samples to assess full blood count, serum folate, vitamin
B12, iron and CD antibodies levels.
Two female patients, without any further systemic signs and
symptoms were found to have positive CD antibodies associated
with haematinic deficiencies, underwent small intestinal biopsy
arising the diagnosis of CD and were revaluated after 6 months of
GFD. They presented atrophic ⁄ erosive OLP localized on the buc-
cal mucosa (associated with a burning sensation despite topical
corticosteroid therapy).
Six months after GFD, a normalization of serum levels of folate,
vitamin B12 and iron, accompanied by an improvement of the
oral soreness and of the atrophic ⁄ erosive areas, were observed in
both patients.
OLP is a chronic disease affecting the oral mucosa, having a
T-cell-mediated autoimmune pathogenesis and an unknown aeti-
ology in most cases.6 It may be associated with a number of
immune-mediated systemic disorders, although this association
could be merely accidental and not linked to the autoimmune
pathogenesis.7
Despite their similar autoimmune pathogenesis and the findings
of the association between CD and oral manifestations,1 few stud-
ies, often with conflicting results, have assessed the association
between CD in OLP patients.
The first association between these two conditions was
reported2 in the case of a 70-year-old male with a biopsy-proven
erosive OLP. Iron, folate and vitamin B12 deficiencies indicated a
jejunal biopsy, which demonstrated the presence of CD. Surpris-
ingly, GFD was found to relieve OLP within six months. The
hypothesis of an association between CD and OLP has been
promptly refuted by Scully et al.,3 who did not diagnosed CD in
none of the 103 OLP patients investigated, concluding that their
association could be only accidental. However, another study
revealed that of the 39 OLP patients recruited, 22 showed positive
CD antibodies.4 Finally, a case of a 9-year-old women with erosive
lichen planus associated with hyper IgE syndrome and CD was
also described.5
Our results, obtained from a small sample size, do not allow us
to confirm any pathogenic association between CD and OLP, but
they represent an interesting observation.
Some atrophic ⁄ erosive and ulcerative oral lesions may be asso-
ciated with underlying haematinic deficiencies,8,9 which could
characterize the nutrient malabsorption status of CD patients.
Both vitamin B12 and folic acid favour tissue tropism, principally
acting on all tissues, as the oral epithelium, with a cell turnover
promoting their regeneration.10 Therefore, the haematinic defi-
ciency in our patients may negatively influence the rapidly divid-
ing mucosal cells affected by a pre-existing OLP. The resolution of
the burning sensation, the amelioration of the atrophic ⁄ erosive
areas and haematinic level normalization after GFD, observed in
our patients with OLP refractory to local therapy, support the
hypothesis of a cause-effect correlation between haematinic defi-
ciencies and the soreness associated with atrophic ⁄ erosive oral
lesions.
In conclusion, as an improvement in nutritional status leads
to relief in oral soreness as opposed to the often less successful
palliative medications, we suggest the search for possible nutri-
tional deficiencies in any patient with atrophic ⁄ erosive oral
lesions, including OLP, and subsequently to include a screening
for CD.
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A shortened docetaxel
desensitization protocol for use
in special cases
Editor
We report a successful shortened docetaxel desensitization proto-
col in a patient with docetaxel hypersensitivity.
A 62-year-old male Caucasian patient presented with a metasta-
sized carcinoma of the prostate, which had been diagnosed 5 years
ago. Treatment with anti-androgen therapy by the department of
urology initially led to stable prostate specific antigen (PSA) levels
and stopped growth of metastases.
When PSA-levels and metastatic growth increased again, the
patient received a docetaxel chemotherapy. Docetaxel was admin-
istered with 75 mg ⁄m2 body surface. The first infusion was well
tolerated, except of mild dyspnoea and moderate increase in blood
pressure.
The second infusion 4 weeks later had to be stopped after a few
minutes due to generalized flush, massive dyspnoea and an associ-
ated hypertensive crisis.
The patient was transferred to our department for diagnosis
and treatment. A skin prick test with docetaxel 40 mg ⁄mL in
physiological saline was negative. An intradermal test showed a
positive reaction only at 0.4 mg ⁄mL, but not at 0.04 mg ⁄mL,
which is rather compatible with an irritative than an allergic skin
test reaction (Fig. 1).1
Premedication included oral glucocorticosteroids 12 and 6 h
before and i.v. H1-antihistamines in 500 mL sodium chloride
30 min before the therapy.
Emergency back up was warranted by electrocardiogram-, oxy-
gen- and blood pressure monitoring, emergency medication avail-
ability, venous access, oxygen bottle and mask and supervision by
medical staff.
After clinical and laboratory assessment of the patient, the first
desensitization-infusion was initiated, following the 5.8 h paclit-
axel desensitization scheme by Feldweg et al.2 (Table 1). This was
tolerated very well, as was the second infusion 4 weeks later. No
immediate or delayed hypersensitivity reaction was observed.
For practical reasons, the third and fourth infusions were
administered according to a shortened 4.8 h desensitization
scheme (Table 2). Later on, this scheme has been used for the
remaining infusions without adverse events.
Comments
Docetaxel is a well-known cytotoxic agent belonging to the group
of taxanes, used in treatment of different cancers of the breast,
lung, ovary, pancreas and other tissues.3
Figure 1 Intradermal test at a level of 1 : 100 diluted docetaxel
solution, positive reaction, presumably irritative.
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